Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
PHASQ Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: August 03, 2023
Report Source: 2022 2nd Quarter Report
PhaseBio Pharmaceuticals Inc. Stock Analysis PHASQ
United States Health Care Nano Cap Report: PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The firm is focused on the development and commercialization of novel therapies for cardiovascular diseases. Its lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. The firm is also developing its preclinical product candidate, PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension. The firm is leveraging ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates. Its focus is on proteins and peptides that are scientifically or clinically validated.
Read More PhaseBio Pharmaceuticals Inc (PHASQ) Chart
Financial Metrics & Statements of PhaseBio Pharmaceuticals Inc (PHASQ)
FAQ's for PhaseBio Pharmaceuticals Inc (PHASQ)
- According to Musaffa’s Shariah screening methodology, PhaseBio Pharmaceuticals Inc (PHASQ) is currently classified as NOT HALAL as of August 2023. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes PhaseBio Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in PhaseBio Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of PhaseBio Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of PhaseBio Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of PhaseBio Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.